{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T15:04:41Z","timestamp":1786115081289,"version":"build-2736575974"},"reference-count":58,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T00:00:00Z","timestamp":1760918400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100027610","name":"TMCity","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100027610","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["AG072654"],"award-info":[{"award-number":["AG072654"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["AG068753"],"award-info":[{"award-number":["AG068753"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["2P30AG013846"],"award-info":[{"award-number":["2P30AG013846"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["AG062109"],"award-info":[{"award-number":["AG062109"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000968","name":"American Heart Association Inc","doi-asserted-by":"publisher","award":["20SFRN35360180"],"award-info":[{"award-number":["20SFRN35360180"]}],"id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002565","name":"Alzheimer's Drug Discovery Foundation","doi-asserted-by":"publisher","award":["201902-2017835"],"award-info":[{"award-number":["201902-2017835"]}],"id":[{"id":"10.13039\/100002565","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Prevention of Alzheimer's Disease"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.tjpad.2025.100395","type":"journal-article","created":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:02:47Z","timestamp":1764547367000},"page":"100395","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Reinventing \u201cN\u201d in the A\/T\/N framework: The case for digital"],"prefix":"10.1016","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7742-4491","authenticated-orcid":false,"given":"Rhoda","family":"Au","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary","family":"Popp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1841-6701","authenticated-orcid":false,"given":"Spencer","family":"Low","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas J.","family":"Ashton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3930-4354","authenticated-orcid":false,"given":"Henrik","family":"Zetterberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tjpad.2025.100395_bib0001","unstructured":"Roche Alzheimer\u2019s disease cerebrospinal fluid (CSF) assays receive FDA clearance, supporting more accurate and timely diagnosis. | 2022| https:\/\/diagnostics.roche.com\/us\/en\/news-listing\/2022\/roche-alzheimers-disease-cerebrospinal-fluid-assays-receive-fda-clearance.html."},{"key":"10.1016\/j.tjpad.2025.100395_bib0003","unstructured":"Quanterix\u2019s Alzheimer\u2019s blood test designated a breakthrough device | 2021-10-15 | FDAnews. https:\/\/www.fdanews.com\/articles\/204866-quanterixs-alzheimers-blood-test-designated-a-breakthrough-device."},{"key":"10.1016\/j.tjpad.2025.100395_bib0004","unstructured":"FDA clears first blood test used in diagnosing Alzheimer\u2019s disease | 2025 |. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-clears-first-blood-test-used-diagnosing-alzheimers-disease."},{"key":"10.1016\/j.tjpad.2025.100395_bib0005","article-title":"Diagnostic accuracy of the plasma ALZpath pTau217 immunoassay to identify Alzheimer\u2019s disease pathology","author":"Ashton","year":"2023","journal-title":"medRxiv"},{"key":"10.1016\/j.tjpad.2025.100395_bib0006","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1001\/jamaneurol.2022.3392","article-title":"Association of Donanemab treatment with exploratory plasma biomarkers in early symptomatic Alzheimer disease: a secondary analysis of the TRAILBLAZER-ALZ randomized clinical trial","volume":"79","author":"Pontecorvo","year":"2022","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.tjpad.2025.100395_bib0007","article-title":"Blood neurofilament light in remote settings: alternative protocols to support sample collection in challenging pre-analytical conditions","volume":"13","author":"Simr\u00e9n","year":"2021","journal-title":"Alzheimers Dement (Amst)"},{"key":"10.1016\/j.tjpad.2025.100395_bib0008","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1136\/jnnp-2021-326603","article-title":"Use of plasma biomarkers for AT(N) classification of neurodegenerative dementias","volume":"92","author":"Alcolea","year":"2021","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.tjpad.2025.100395_bib0009","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13195-018-0404-9","article-title":"Plasma neurofilament light as a potential biomarker of neurodegeneration in Alzheimer\u2019s disease","volume":"10","author":"Lewczuk","year":"2018","journal-title":"Alzheimers Res Ther"},{"key":"10.1016\/j.tjpad.2025.100395_bib0010","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-23620-z","article-title":"A multicentre validation study of the diagnostic value of plasma neurofilament light","volume":"12","author":"Ashton","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.tjpad.2025.100395_bib0011","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1001\/jamaneurol.2021.0285","article-title":"Diversity and disparities in dementia diagnosis and care: a challenge for all of us","volume":"78","author":"Kawas","year":"2021","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.tjpad.2025.100395_bib0012","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.jalz.2012.04.004","article-title":"The draft \u201cNational Plan\u201d to address Alzheimer\u2019s disease - National Alzheimer\u2019s Project Act (NAPA)","volume":"8","author":"Khachaturian","year":"2012","journal-title":"Alzheimer\u2019s Dement."},{"key":"10.1016\/j.tjpad.2025.100395_bib0013","doi-asserted-by":"crossref","first-page":"398","DOI":"10.14283\/jpad.2021.41","article-title":"Aducanumab: appropriate use recommendations","volume":"8","author":"Cummings","year":"2021","journal-title":"J Prev Alzheimers Dis"},{"key":"10.1016\/j.tjpad.2025.100395_bib0014","article-title":"Lecanemab in early Alzheimer\u2019s Disease","author":"van Dyck","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tjpad.2025.100395_bib0015","unstructured":"FDA approves treatment for adults with Alzheimer\u2019s disease | 2025 | https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fda-approves-treatment-adults-alzheimers-disease."},{"key":"10.1016\/j.tjpad.2025.100395_bib0016","doi-asserted-by":"crossref","DOI":"10.1186\/s13195-019-0543-7","article-title":"Testing the 2018 NIA-AA research framework in a retrospective large cohort of patients with cognitive impairment: from biological biomarkers to clinical syndromes","volume":"11","author":"Carandini","year":"2019","journal-title":"Alzheimers Res Ther"},{"key":"10.1016\/j.tjpad.2025.100395_bib0018","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.31654","article-title":"Association of cognitive function trajectories in centenarians with postmortem neuropathology, physical health, and other risk factors for cognitive decline","volume":"4","author":"Beker","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.tjpad.2025.100395_bib0017","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1001\/jamaneurol.2022.3157","article-title":"Racial and ethnic differences in amyloid PET positivity in individuals with mild cognitive impairment or dementia: a secondary analysis of the imaging dementia\u2013Evidence for amyloid scanning (IDEAS) cohort study","volume":"79","author":"Wilkins","year":"2022","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.tjpad.2025.100395_bib0019","doi-asserted-by":"crossref","first-page":"829","DOI":"10.3233\/JAD-191227","article-title":"The amyloid, tau, and neurodegeneration (A\/T\/N) classification applied to a clinical research cohort with long-term follow-up","volume":"74","author":"Gr\u00f8ntvedt","year":"2020","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"10.1016\/j.tjpad.2025.100395_bib0020","first-page":"1183","article-title":"Synergy between amyloid-\u03b2 and tau in Alzheimer\u2019s disease","volume":"23","author":"Busche","year":"2020","journal-title":"Nat. Neurosci. 2020 23:10"},{"key":"10.1016\/j.tjpad.2025.100395_bib0021","first-page":"346","article-title":"Challenges associated with biomarker-based classification systems for Alzheimer\u2019s disease","volume":"10","author":"Ill\u00e1n-Gala","year":"2018","journal-title":"Alzheimer\u2019s Dement.: Diagn. Assess. Dis. Monit."},{"key":"10.1016\/j.tjpad.2025.100395_bib0022","doi-asserted-by":"crossref","first-page":"395","DOI":"10.3233\/JAD-181152","article-title":"Cerebrospinal fluid and plasma biomarkers in neurodegenerative diseases","volume":"68","author":"Seino","year":"2019","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"10.1016\/j.tjpad.2025.100395_bib0023","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1001\/jamaneurol.2020.4986","article-title":"Longitudinal associations of blood phosphorylated Tau181 and neurofilament light chain with neurodegeneration in Alzheimer disease","volume":"78","author":"Moscoso","year":"2021","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.tjpad.2025.100395_bib0024","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/ane.13415","article-title":"Neurological symptoms and blood neurofilament light levels","volume":"144","author":"Barro","year":"2021","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.tjpad.2025.100395_bib0025","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1001\/jamaneurol.2023.0050","article-title":"Alzheimer Disease blood biomarkers in patients with out-of-hospital cardiac arrest","volume":"80","author":"Ashton","year":"2023","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.tjpad.2025.100395_bib0026","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.3389\/fnins.2021.689938","article-title":"Neurofilament proteins as biomarkers to monitor neurological diseases and the efficacy of therapies","volume":"15","author":"Yuan","year":"2021","journal-title":"Front Neurosci"},{"key":"10.1016\/j.tjpad.2025.100395_bib0027","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1002\/acn3.50972","article-title":"Confounding effect of blood volume and body mass index on blood neurofilament light chain levels","volume":"7","author":"Manouchehrinia","year":"2020","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.tjpad.2025.100395_bib0028","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-76990-7","article-title":"Renal function is associated with blood neurofilament light chain level in older adults","volume":"10","author":"Akamine","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.tjpad.2025.100395_bib0029","first-page":"q281","article-title":"Biogen abandons Alzheimer\u2019s drug after controversial approval left it unfunded by Medicare","volume":"384","author":"Aduhelm","year":"2024","journal-title":"BMJ"},{"key":"10.1016\/j.tjpad.2025.100395_bib0030","doi-asserted-by":"crossref","first-page":"197","DOI":"10.14283\/jpad.2022.30","article-title":"Two randomized phase 3 studies of Aducanumab in early Alzheimer\u2019s disease","volume":"9","author":"Budd Haeberlein","year":"2022","journal-title":"J. Prev. Alzheimer\u2019s Dis."},{"key":"10.1016\/j.tjpad.2025.100395_bib0031","doi-asserted-by":"crossref","unstructured":"Espay A.J., Kepp K.P., Herrup K. Lecanemab and Donanemab as therapies for Alzheimer's Disease: an illustrated perspective on the data. ENeuro. 2024 Jul 1;11(7):ENEURO.0319-23.2024. doi: 10.1523\/ENEURO.0319-23.2024. PMID: 38951040; PMCID: PMC11218032.","DOI":"10.1523\/ENEURO.0319-23.2024"},{"key":"10.1016\/j.tjpad.2025.100395_bib0032","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/jnc.15023","article-title":"What works and what does not work in Alzheimer\u2019s disease? From interventions on risk factors to anti-amyloid trials","volume":"155","author":"Bullain","year":"2020","journal-title":"J Neurochem"},{"key":"10.1016\/j.tjpad.2025.100395_bib0033","doi-asserted-by":"crossref","first-page":"423","DOI":"10.3233\/JAD-170991","article-title":"The Alzheimer\u2019s Disease Assessment Scale\u2013Cognitive Subscale (ADAS-Cog): modifications and responsiveness in pre-dementia populations. A narrative review","volume":"63","author":"Kueper","year":"2018","journal-title":"J Alzheimer\u2019s Dis"},{"key":"10.1016\/j.tjpad.2025.100395_bib0034","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1111\/psyg.12647","article-title":"Psychometric properties of outcome measures in non-pharmacological interventions of persons with dementia in low-and middle-income countries: a systematic review","volume":"vol. 21","author":"Du","year":"2021","journal-title":"Psychogeriatrics"},{"key":"10.1016\/j.tjpad.2025.100395_bib0035","first-page":"13","article-title":"Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer\u2019s Disease assessment scale that broaden its scope","volume":"11","author":"Mohs","year":"1997","journal-title":"Undefined"},{"key":"10.1016\/j.tjpad.2025.100395_bib0036","first-page":"e1","article-title":"Recent publications from the Alzheimer\u2019s Disease Neuroimaging Initiative: reviewing progress toward improved AD clinical trials","volume":"13","author":"Weiner","year":"2017","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.tjpad.2025.100395_bib0037","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1136\/jnnp-2015-312383","article-title":"ADCOMS: a composite clinical outcome for prodromal Alzheimer\u2019s disease trials","volume":"87","author":"Wang","year":"2016","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.tjpad.2025.100395_bib0038","article-title":"A new rating scale for Alzheimer\u2019s disease","volume":"141","author":"Rosen","year":"1984","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.tjpad.2025.100395_bib0039","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","article-title":"Mini-mental state\u201d: a practical method for grading the cognitive state of patients for the clinician","volume":"12","author":"Folstein","year":"1975","journal-title":"J Psychiatr Res"},{"key":"10.1016\/j.tjpad.2025.100395_bib0040","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1212\/WNL.39.9.1159","article-title":"The Consortium to Establish a Registry for Alzheimer\u2019s Disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer\u2019s disease","volume":"39","author":"Morris","year":"1989","journal-title":"Neurology"},{"key":"10.1016\/j.tjpad.2025.100395_bib0041","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1097\/WAD.0000000000000508","article-title":"Increasing the Cognitive screening efficiency of global phase III trials in early Alzheimer disease: the cognitive task force","volume":"36","author":"Doherty","year":"2022","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"10.1016\/j.tjpad.2025.100395_bib0042","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1192\/bjo.2021.1067","article-title":"Developing guidelines for the translation and cultural adaptation of the Montreal Cognitive Assessment: scoping review and qualitative synthesis","volume":"8","author":"Khan","year":"2022","journal-title":"BJPsych Open"},{"key":"10.1016\/j.tjpad.2025.100395_bib0043","doi-asserted-by":"crossref","DOI":"10.1038\/s41386-020-0771-3","article-title":"Opportunities and challenges in the collection and analysis of digital phenotyping data","author":"Onnela","year":"2021","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.tjpad.2025.100395_bib0044","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1007\/s40473-020-00215-4","article-title":"Digital phenotyping using multimodal data","volume":"7","author":"Cohen","year":"2020","journal-title":"Curr Behav Neurosci Rep"},{"key":"10.1016\/j.tjpad.2025.100395_bib0045","doi-asserted-by":"crossref","first-page":"i180","DOI":"10.1093\/geronb\/gbq095","article-title":"Intelligent systems for assessing aging changes: home-based, unobtrusive, and continuous assessment of aging","author":"Kaye","year":"2011","journal-title":"J Gerontol B Psychol Sci Soc Sci 66B"},{"key":"10.1016\/j.tjpad.2025.100395_bib0046","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.jalz.2017.07.756","article-title":"Weekly observations of online survey metadata obtained through home computer use allow for detection of changes in everyday cognition before transition to mild cognitive impairment","volume":"14","author":"Seelye","year":"2018","journal-title":"Alzheimer\u2019s Dement."},{"key":"10.1016\/j.tjpad.2025.100395_bib0047","doi-asserted-by":"crossref","first-page":"713","DOI":"10.3233\/JAD-160079","article-title":"Less daily computer use is related to smaller hippocampal volumes in cognitively intact elderly","volume":"52","author":"Silbert","year":"2016","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.tjpad.2025.100395_bib0048","doi-asserted-by":"crossref","DOI":"10.1016\/j.jalz.2014.07.118","article-title":"P4-348: social biomarkers for early signs of dementia: increased spoken word counts among older adults with Mild cognitive Impairment (MCI)","volume":"10","author":"Kaye","year":"2014","journal-title":"Alzheimer\u2019s Dement."},{"key":"10.1016\/j.tjpad.2025.100395_bib0049","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/WAD.0b013e318211c6c9","article-title":"Diversity and disparity in dementia: the impact of ethnoracial differences in Alzheimer disease","volume":"vol. 25","author":"Chin","year":"2011","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"10.1016\/j.tjpad.2025.100395_bib0050","unstructured":"What is digital health | 2020 |. https:\/\/www.fda.gov\/medical-devices\/digital-health-center-excellence\/what-digital-health."},{"key":"10.1016\/j.tjpad.2025.100395_bib0051","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41746-022-00734-2","article-title":"The evolution of digital health technologies in cardiovascular disease research","volume":"6","author":"Zwack","year":"2023","journal-title":"NPJ Digit, Med"},{"issue":"20","key":"10.1016\/j.tjpad.2025.100395_bib0052","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa1901183","article-title":"Apple heart study investigators. Large-scale assessment of a smartwatch to identify atrial fibrillation","volume":"381","author":"Perez","year":"2019","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.tjpad.2025.100395_bib0053","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.123.031247","article-title":"Shifting from active to passive monitoring of Alzheimer disease: the State of the research","volume":"13","author":"Popp","year":"2024","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.tjpad.2025.100395_bib0054","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1146\/annurev-publhealth-052620-093850","article-title":"Mobile health (mHealth) in low- and middle-income countries","volume":"vol. 43","author":"McCool","year":"2022","journal-title":"Annu Rev Public Health"},{"key":"10.1016\/j.tjpad.2025.100395_bib0055","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1159\/000517885","article-title":"Digital endpoints: definition, benefits, and current barriers in accelerating development and adoption","volume":"vol. 5","author":"Landers","year":"2021","journal-title":"Digit Biomark"},{"key":"10.1016\/j.tjpad.2025.100395_bib0056","doi-asserted-by":"crossref","DOI":"10.3389\/fdgth.2021.751629","article-title":"Redefining and validating digital biomarkers as fluid, dynamic multi-dimensional digital signal patterns","volume":"3","author":"Au","year":"2022","journal-title":"Front Digit Health"},{"issue":"3","key":"10.1016\/j.tjpad.2025.100395_bib0057","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1002\/alz.12450","article-title":"The costs of developing treatments for Alzheimer's disease: a retrospective exploration","volume":"18","author":"Cummings","year":"2022","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.tjpad.2025.100395_bib0058","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.2105\/AJPH.88.9.1337","article-title":"Projections of Alzheimer\u2019s disease in the United States and the public health impact of delaying disease onset","volume":"88","author":"Brookmeyer","year":"1998","journal-title":"Am J Public Health"},{"key":"10.1016\/j.tjpad.2025.100395_bib0059","doi-asserted-by":"crossref","DOI":"10.1038\/s41746-019-0084-2","article-title":"Digital biomarkers for Alzheimer\u2019s disease: the mobile\/wearable devices opportunity","volume":"2","author":"Kourtis","year":"2019","journal-title":"NPJ Digit Med"}],"container-title":["The Journal of Prevention of Alzheimer's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2274580725003371?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2274580725003371?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T00:07:54Z","timestamp":1785974874000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2274580725003371"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":58,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S2274580725003371"],"URL":"https:\/\/doi.org\/10.1016\/j.tjpad.2025.100395","relation":{},"ISSN":["2274-5807"],"issn-type":[{"value":"2274-5807","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reinventing \u201cN\u201d in the A\/T\/N framework: The case for digital","name":"articletitle","label":"Article Title"},{"value":"The Journal of Prevention of Alzheimer's Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tjpad.2025.100395","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Masson SAS on behalf of SERDI Publisher.","name":"copyright","label":"Copyright"}],"article-number":"100395"}}